Board of Directors
Dr. Tony Wild - CHAIRMAN
Dr. Wild has over 30 years’ experience working in the pharmaceutical industry. He has held senior positions in Warner Lambert's Parke-Davis division, Schering Plough and MedPointe Pharmaceuticals. Dr. Wild is a co-founder and General Partner of BOWS Pharmaceuticals AG, a Swiss drug-delivery technology company. He is a member of the Boards of Directors of several privately-owned specialty pharmaceutical and biotechnology companies. He also chairs the board of advisors of Ferrer, Freeman and Co., a healthcare private equity firm. He is on the board of advisors of Celtic Therapeutics, a pharmaceutical venture fund and is an advisor to Golden Pond Healthcare Inc., a special acquisitions corporation. Dr. Wild graduated in 1968 from the University of York where he earned an honours degree in Chemistry. He also holds a Ph.D. degree in physical chemistry from the University of Cambridge (Churchill College).
Rolf Schmidt - DIRECTOR
Mr. Schmidt was co-founder of the medical bio-adhesives product company, Closure Medical Corporation together with his brother William Schmidt. He led the company as Chairman from its early development through IPO in 1996 and up until its acquisition by Johnson & Johnson in 2005. Mr. Schmidt's training and business experience is concentrated mainly in engineering and management roles. He was co-founder of Sharpoint, Inc. a leading developer and manufacturer of ophthalmic surgical needles and sutures prior to its acquisition by Alcon Labs, Inc. in 1986. Mr. Schmidt actively consults with and invests in early-stage healthcare technology companies.
Michael Myers, Ph.D. - DIRECTOR
Dr. Michael Myers is President and Chief Executive Officer of Innocoll Inc. He has over 25 years active experience in the pharmaceutical industry in the US and Europe with a proven track record of development and commercialization of a number of significant drug delivery products across a wide variety of delivery routes. He has served as President of the Drug Delivery division of West Pharmaceutical Services and formerly as President of Pharmaceutical Operations for Fuisz Technologies (Biovail) where he oversaw the development and commercialization of the Company's FlashDose® technology platform. Michael has also held executive positions in Flamel Technologies and Elan Corporation. Michael holds a Ph.D. in Organic Chemistry from the University of Cork.
John O'Meara - DIRECTOR
John O'Meara has over 7 years’ experience in the finance industry. He is currently a Vice President in Morgan Stanley's credit trading business in the Fixed Income Division of Sales and Trading. As a previous member of Morgan Stanley's High Yield Research Team from 2003 - 2007, Mr. O'Meara was a published analyst of High Yield Research. Mr. O'Meara joined the trading desk in 2008 where his responsibilities include reviewing investing opportunities, corporate restructurings and capital market transaction. Mr. O'Meara holds a B.A. in Economics from University of California, Davis.
Dennis H. Langer - M.D., J.D. DIRECTOR
Dr. Langer is a Director of Myriad Genetics, Inc., Myrexis, Inc., and several private health care companies. He has served as a Director of several public and private biotechnology, specialty pharmaceutical and diagnostic companies, including Sirna Therapeutics, Inc. (acquired by Merck & Co., Inc.), Ception Therapeutics, Inc. (acquired by Cephalon, Inc.), Transkaryotic Therapies, Inc. (acquired by Shire plc), Pharmacopeia, Inc. (acquired by Ligand, Inc.), and Cytogen Corporation (acquired by EUSA Pharma, Inc.). He was a Managing Partner at Phoenix IP Ventures, LLC from 2005-2010. From 2004-2005, he was President, North America for Dr. Reddy's Laboratories, Inc. Dr. Langer was with GlaxoSmithKline from 1994-2004, where he served as Senior Vice President, Project, Portfolio and Alliance Management, Senior Vice President, Product Development Strategy, and Senior Vice President, Healthcare Services R&D. He also served as President and CEO at Neose Technologies, Inc. from 1991-1994. Previously, Dr. Langer held R&D and marketing positions at Eli Lilly, Abbott, and Searle.
Dr. Langer is a Clinical Professor in the Department of Psychiatry at Georgetown University School of Medicine. He was Chief Resident in Psychiatry at Yale University School of Medicine and held clinical fellowships at Harvard Medical School and the National Institutes of Health. Dr. Langer serves on the Dean's Advisory Board of Harvard Law School and the Committee on Medical Center Affairs of the Board of Directors of Georgetown University. He received an M.D. from Georgetown University School of Medicine, a J.D. (cum laude) from Harvard Law School, and a B.A. in Biology from Columbia University.
James Culverwell - DIRECTOR
James has over 30 years experience in the pharmaceutical industry through a successful career in pharmaceutical company analysis, investment banking and latterly in healthcare private equity. After graduating fom the University of Aberdeen (MSc), James joined Hoare Govett in 1982 where he became Director of European Healthcare Research. He joined Merrill Lynch in 1995, where he became Head of European Pharmaceutical Research and Global Co-ordinator for Healthcare Research and established a top-rated franchise. In 2004 James set up Sudbrook Associates, a small healthcare corporate advisor specialising in fund raising, corporate advice and due diligence in the private healthcare sector. James also sits on the board of four other companies in the specialty pharma, drug development and diagnostic field.